The prevalence of urogenital Chlamydia trachomatis infection was determined with a PCR-
based test of women from low-and high-risk populations in Iloilo City, Philippines, between …

Of 1,493 encounters of males at a sexually transmitted infection (STI) clinic in a community
with a high prevalence of STI, Chlamydia trachomatis was detected in 8.7% and Neisseria …

The APTIMA® transcription-mediated amplification assays for Chlamydia trachomatis and
Neisseria gonorrhoeae have the greatest sensitivity of all the commercial nucleic acid …

Background Trachoma is the leading infectious cause of blindness due to conjunctival
infection with Chlamydia trachomatis. The presence of active trachoma and evidence of …

Trichomonas vaginalis infection in males has been largely uncharacterized. Past reports
indicated increased susceptibility to other sexually transmitted infection (STI) agents such as …

Background Nucleic acid amplification tests (NAAT) are well-accepted in diagnosis and
surveillance of sexually infectious pathogens worldwide. However, performance differences …

Background/Aim: The World Health Organisation (WHO) hopes to achieve global elimination
of trachoma, still the leading cause of preventable blindness worldwide, in part through …

purpose. Trachoma remains the leading infectious cause of blindness worldwide. The World
Health Organization (WHO) recommends mass antibiotic distributions in its strategy to …

Chlamydia, with its Chlamydia trachomatis etiology, is the most common bacterial sexually
transmitted infection in the United States and is often transmitted via asymptomatic …

The APTIMA COMBO 2 assay, which detects and amplifies rRNA from Chlamydia
trachomatis and/or Neisseria gonorrhoeae, is approved for use on ThinPrep liquid-based …